Patent classifications
C07D498/06
Antiviral compounds highly effective as HCV-NS5A inhibitor
Provided are compounds antiviral compounds represented by formula Ia and Ib: ##STR00001##
that are highly potent as HCV NS5A inhibitors, where the structural variables are as defined herein. These compounds are useful in, for example, inhibiting Hepatitis C virus and treating Hepatitis C virus infections.
Compounds for electronic devices
The present invention relates to compounds of the formula (1), (17) 18) or (20) and to the use thereof in electronic devices, and to electronic devices which contain these compounds. The invention furthermore relates to the preparation of the compounds of the formula (1), (17) 18) or (20) and to formulations contains one or more compounds of the formula (1), (17) 18) or (20).
Compounds for electronic devices
The present invention relates to compounds of the formula (1), (17) 18) or (20) and to the use thereof in electronic devices, and to electronic devices which contain these compounds. The invention furthermore relates to the preparation of the compounds of the formula (1), (17) 18) or (20) and to formulations contains one or more compounds of the formula (1), (17) 18) or (20).
Compounds and methods for targeting HSP90
Described herein are compounds that may selectively bind to Hsp90, methods of using the compounds, and kits including the compounds. The compounds may allow for selective detection of Hsp90 in a sample.
Compounds and methods for targeting HSP90
Described herein are compounds that may selectively bind to Hsp90, methods of using the compounds, and kits including the compounds. The compounds may allow for selective detection of Hsp90 in a sample.
Condensed-cyclic compound and organic light-emitting device including the same
A condensed cyclic compound is represented by Formula 1 below: ##STR00001##
wherein X.sub.3 is a carbon atom that is one of X.sub.7 and X.sub.8 in Formula A below, X4 is a carbon atom that is the other of X.sub.7 and X.sub.8 in Formula A, or ii) X.sub.5 is a carbon atom that is one of X.sub.7 and X.sub.8 in Formula A, X.sub.6 is a carbon atom that is the other of X.sub.7 and X.sub.8 in Formula A, ##STR00002##
Condensed-cyclic compound and organic light-emitting device including the same
A condensed cyclic compound is represented by Formula 1 below: ##STR00001##
wherein X.sub.3 is a carbon atom that is one of X.sub.7 and X.sub.8 in Formula A below, X4 is a carbon atom that is the other of X.sub.7 and X.sub.8 in Formula A, or ii) X.sub.5 is a carbon atom that is one of X.sub.7 and X.sub.8 in Formula A, X.sub.6 is a carbon atom that is the other of X.sub.7 and X.sub.8 in Formula A, ##STR00002##
TRICYCLIC COMPOUNDS AS STING AGONISTS, AND PREPARATION METHODS AND MEDICINAL USES THEREOF
Compounds of formula (I) useful as agonists of stimulator of interferon genes (STING), the preparation method therefor, pharmaceutical compositions comprising the compounds, and the pharmaceutical uses for the treatment of STING-mediated diseases or disorders are disclosed.
##STR00001##
TRICYCLIC COMPOUNDS AS STING AGONISTS, AND PREPARATION METHODS AND MEDICINAL USES THEREOF
Compounds of formula (I) useful as agonists of stimulator of interferon genes (STING), the preparation method therefor, pharmaceutical compositions comprising the compounds, and the pharmaceutical uses for the treatment of STING-mediated diseases or disorders are disclosed.
##STR00001##
Biologically active macrolides, compositions, and uses thereof
The present invention provides a compound of the formula (I) or (II), wherein R.sup.1 is H, alkyl, alkenyl or aryl, R.sup.2 is H, alkyl or aryl, R.sup.3 is H, a alkyl, alkenyl or aryl, R.sup.4 and R.sup.4-R.sup.8 are independently R.sup.10, C(O)R.sup.10 or SO.sub.2R.sup.10, wherein R.sup.10 is H, alkyl, alkenyl or aryl, and R.sup.9 is R.sup.9a, C(O)R.sup.9a or SO.sub.2R.sup.9a, wherein R.sup.9a is H, alkyl, alkenyl or aryl. R.sup.9a can be unsubstituted or substituted with one or more oxo(═O), OR.sup.9b, OC(O)R.sup.9b, OSO.sub.2R.sup.9b, NHR.sup.9b, NHC(O)R.sup.9b and NHSO.sub.2R.sup.9b groups. R.sup.9b is H, alkyl, alkenyl, or aryl. R.sup.9b can be unsubstituted or substituted with one or more groups such as oxo(═O), OR.sup.9c, CO.sub.2R.sup.9c, CO.sub.2R.sup.9c and OC(O)R.sup.9c. R.sup.9c is H, or a unsubstituted or substituted alkyl, alkenyl or aryl. The present invention further provides a composition comprising at least one compound of the present invention and a pharmaceutically acceptable carrier, alone or in combination with at least one additional active agent. The present invention further provides a method of treating a condition treatable by the inhibition of vacuolar-type (H+)-ATPase and a method of treating cancer. ##STR00001##